Świtońska Milena, Słomka Artur, Piekuś-Słomka Natalia, Żekanowska Ewa, Meder Grzegorz, Sokal Paweł, Lattanzi Simona
Department of Neurosurgery and Neurology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum, Faculty of Health Sciences, Bydgoszcz, Poland.
Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz.
Neurol Neurochir Pol. 2022;56(2):171-177. doi: 10.5603/PJNNS.a2022.0018. Epub 2022 Feb 14.
Accurately predicting outcomes after acute ischaemic stroke (AIS) is a major clinical goal. The aim of this pilot study was to evaluate the prognostic validity and accuracy of the Acute Stroke Registry and Analysis of Lausanne (ASTRAL) score in predicting symptomatic haemorrhagic transformation (sHT) in patients with AIS who have undergone revascularisation.
Consecutive patients hospitalised for AIS who underwent treatment with intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT) were identified, and their ASTRAL scores at hospital admission were estimated. The study endpoint was sHT within 24 hours of stroke onset. The predictive performance of the ASTRAL score was investigated through logistic regression analysis and discrimination and calibration tests.
Sixty-eight AIS patients, with a median age of 69 (58-79) years, were included. sHT occurred in 20 (29.4%) of the 68 patients. The ASTRAL score was significantly higher in patients who developed sHT compared to non-sHT patients [36 (34-38) versus 24 (17-32); p<0.001]. The ASTRAL score was an independent predictor of sHT, and showed good discriminative power (area under the curve 0.88; 95% confidence interval, 0.789-0.965).
ASTRAL score is an independent predictor of sHT and shows high predictive accuracy in patients with AIS. Future studies are warranted to confirm these results.
准确预测急性缺血性卒中(AIS)后的预后是一项主要的临床目标。本试点研究的目的是评估洛桑急性卒中登记与分析(ASTRAL)评分在预测接受血管再通治疗的AIS患者症状性出血转化(sHT)方面的预后有效性和准确性。
确定因AIS住院并接受静脉溶栓(IVT)和/或机械取栓(MT)治疗的连续患者,并估算其入院时的ASTRAL评分。研究终点为卒中发作后24小时内的sHT。通过逻辑回归分析以及鉴别和校准测试研究ASTRAL评分的预测性能。
纳入68例AIS患者,中位年龄为69(58 - 79)岁。68例患者中有20例(29.4%)发生sHT。发生sHT的患者的ASTRAL评分显著高于未发生sHT的患者[36(34 - 38)对24(17 - 32);p<0.001]。ASTRAL评分是sHT的独立预测因素,且具有良好的鉴别能力(曲线下面积为0.88;95%置信区间,0.789 - 0.965)。
ASTRAL评分是sHT的独立预测因素,在AIS患者中显示出较高的预测准确性。未来有必要进行研究以证实这些结果。